Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2018 1
2020 4
2021 4
2022 2
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL.
Hengeveld PJ, Kolijn PM, Demmers JAA, Doff W, Dubois JMN, Rijken M, Assmann JLJC, van der Straten L, Boiten HJ, Gussinklo KJ, Valk PJM, Faber LM, Westerweel PE, Kater AP, Levin MD, Langerak AW. Hengeveld PJ, et al. Hemasphere. 2023 Sep 15;7(10):e951. doi: 10.1097/HS9.0000000000000951. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37731707 Free PMC article.
Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.
Hengeveld PJ, Veelken H, van Bergen CAM, Quinten E, Vervoordeldonk MYL, Ismailzada W, Barendse RS, Dubois JMN, van Oers MHJ, Geisler CH, Kater AP, Westerweel PE, Langerak AW, Levin MD. Hengeveld PJ, et al. Leukemia. 2023 Sep;37(9):1929-1932. doi: 10.1038/s41375-023-01975-0. Epub 2023 Jul 21. Leukemia. 2023. PMID: 37479761 Free PMC article. No abstract available.
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Hengeveld PJ, Schilperoord-Vermeulen J, van der Klift MY, Dubois JMN, Kolijn PM, Kavelaars FG, Rijken M, Dobber JA, Nasserinejad K, Kersting S, Westerweel PE, Kater AP, Langerak AW, Levin MD. Hengeveld PJ, et al. Blood Cancer J. 2023 Jul 4;13(1):102. doi: 10.1038/s41408-023-00870-2. Blood Cancer J. 2023. PMID: 37400508 Free PMC article. No abstract available.
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews GM, Barwick BG, Gupta VA, Dupéré-Richer D, Yamano S, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Ishiguro K, Meyers RM, Bryan JG, Dharia NV, Hengeveld PJ, Brüggenthies JB, Tang H, Aguirre AJ, Sievers QL, Ebert BL, Glassner BJ, Ott CJ, Bradner JE, Kwiatkowski NP, Auclair D, Levy J, Keats JJ, Groen RWJ, Gray NS, Culhane AC, McFarland JM, Dempster JM, Licht JD, Boise LH, Hahn WC, Vazquez F, Tsherniak A, Mitsiades CS. de Matos Simoes R, et al. Among authors: hengeveld pj. Nat Cancer. 2023 May;4(5):754-773. doi: 10.1038/s43018-023-00550-x. Epub 2023 May 26. Nat Cancer. 2023. PMID: 37237081
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, Robrecht S, Assmann JLJC, van der Straten L, Ritgen M, Westerweel PE, Fischer K, Goede V, Hallek M, Levin MD, Langerak AW. Hengeveld PJ, et al. Blood. 2023 Feb 2;141(5):519-528. doi: 10.1182/blood.2022017411. Blood. 2023. PMID: 36084320 Free article.
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110.
Hengeveld PJ, Ertem YE, Dubois JMN, Mellink CHM, van der Kevie-Kersemaekers AM, Evers LM, Heezen K, Kolijn PM, Mook ORF, Motazacker MM, Nasserinejad K, Kersting S, Westerweel PE, Niemann CU, Kater AP, Langerak AW, Levin MD. Hengeveld PJ, et al. Leukemia. 2022 Jul;36(7):1935-1938. doi: 10.1038/s41375-022-01600-6. Epub 2022 May 18. Leukemia. 2022. PMID: 35585140 No abstract available.
High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis.
Kolijn PM, Hosnijeh FS, Späth F, Hengeveld PJ, Agathangelidis A, Saleh M, Casabonne D, Benavente Y, Jerkeman M, Agudo A, Barricarte A, Besson C, Sánchez MJ, Chirlaque MD, Masala G, Sacerdote C, Grioni S, Schulze MB, Nieters A, Engelfriet P, Hultdin M, McKay JD, Vermeulen RCH, Langerak AW. Kolijn PM, et al. Among authors: hengeveld pj. Blood. 2022 Mar 10;139(10):1557-1563. doi: 10.1182/blood.2021012890. Blood. 2022. PMID: 34662377 Free PMC article.
19 results